Vor Biopharma (VOR) Share-based Compensation (2020 - 2026)
Vor Biopharma (VOR) reported Share-based Compensation of $8.9 million for Q1 2026, up 358.87% year-over-year from $1.9 million in Q1 2025, and up 24.82% on a QoQ basis from $7.1 million in Q4 2025.
Vor Biopharma (VOR) has 7 years of Share-based Compensation data on file, last reported at $8.9 million in Q1 2026.
- Quarterly Share-based Compensation rose 358.87% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (up 197.15% YoY) and the FY2025 annual result came in at $18.9 million, up 92.06% from the prior year.
- Share-based Compensation rose to $8.9 million in Q1 2026 per VOR's latest filing, from $7.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.9 million in Q1 2026 and bottomed at $1.7 million in Q4 2024.
- The 5-year median for Share-based Compensation is $3.1 million (2024), against an average of $3.6 million.
- The widest annual swing landed in 2023, when Share-based Compensation plunged 51.17%; it then surged 358.87% in 2026.
- Tracing VOR's Share-based Compensation over 5 years: stood at $3.9 million in 2022, then sank by 51.17% to $1.9 million in 2023, then declined by 9.77% to $1.7 million in 2024, then surged by 315.8% to $7.1 million in 2025, then gained by 24.82% to $8.9 million in 2026.
- Per Business Quant, the three latest VOR Share-based Compensation figures stand at $8.9 million (Q1 2026), $7.1 million (Q4 2025), and $8.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | 8.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.87 Mn |
| Mar 31, 2026 | 8.87 Mn |
| Dec 31, 2025 | 7.11 Mn |
| Dec 31, 2025 | 7.11 Mn |
| Sep 30, 2025 | 8.03 Mn |
| Sep 30, 2025 | 8.03 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 2.26 Mn |
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 3.08 Mn |
| Mar 31, 2024 | 3.08 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | 3.16 Mn |
| Sep 30, 2023 | 3.16 Mn |
| Jun 30, 2023 | 4.24 Mn |
| Jun 30, 2023 | 4.24 Mn |
| Mar 31, 2023 | 4.07 Mn |
| Mar 31, 2023 | 4.07 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | 3.33 Mn |
| Sep 30, 2022 | 3.33 Mn |
| Jun 30, 2022 | 1.74 Mn |
| Jun 30, 2022 | 1.74 Mn |
| Mar 31, 2022 | 1.75 Mn |
| Mar 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 1.20 Mn |
| Dec 31, 2021 | 1.20 Mn |
| Sep 30, 2021 | 1.15 Mn |
| Sep 30, 2021 | 1.15 Mn |
| Jun 30, 2021 | 1.07 Mn |
| Jun 30, 2021 | 1.07 Mn |
| Mar 31, 2021 | 891,000.00 |
| Mar 31, 2021 | 891,000.00 |
| Dec 31, 2020 | 594,000.00 |
| Dec 31, 2020 | 594,000.00 |
| Sep 30, 2020 | 483,000.00 |
| Sep 30, 2020 | 483,000.00 |
| Jun 30, 2020 | 153,000.00 |
| Jun 30, 2020 | 153,000.00 |
| Mar 31, 2020 | 112,000.00 |
| Mar 31, 2020 | 112,000.00 |